Clearside Biomedical presents additional positive PEACHTREE data in treating uveitic macular edema

Clearside Biomedical (NASDAQ:CLSD) presented additional data from its Phase 3 PEACHTREE trial of XIPERE in patients with uveitic macular edema at the American Academy of Ophthalmology 2018 annual meeting.

At the meeting, Dr. Rahul Khurana, a vitreoretinal surgeon and principal investigator for PEACHTREE, presented a new analysis of the change in best corrected visual acuity, or BCVA, in patients with each anatomical location of uveitis - Anterior, Intermediate, Posterior and Panuveitis:

 
CLSD-chart.jpg
 

Unlike current therapies, which have shown efficacy in certain locations of uveitis, such as anterior or posterior segment uveitis, Dr. Khurana said patients treated with XIPERE in the PEACHTREE trial achieved visual improvement across all anatomical locations of uveitis. “This serves to further differentiate the impressive clinical profile of XIPERE,” he added.

Dr. Khurana also presented new analyses of resolution of clinically significant vitreous haze. At week 24 in the PEACHTREE trial, 40.9% of patients with baseline scores of 2+ vitreous haze, based on the Standardization of Uveitis Nomenclature scale, experienced resolution in the XIPERE arm, compared with 0% of patients in the control arm who underwent a sham procedure.

“These additional data add to my confidence that XIPERE holds promise for my patients with uveitic macular edema,” Dr. Khurana said of the two new analyses.

Melane LaBelle Sampson